Gilead pens dual-purpose $2B Ouro M&A deal with Galapagos

AI Briefing

• – Gilead to acquire Ouro Medicines for $2.17B, expand autoimmune portfolio.
• – Acquisition includes gamgertamig, BCMA/CD3 bispecific T-cell engager.
• – Deal valued at $2.17 billion, expected to close in 2023.